denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: Managing Thrombocytopenia in Challenging Situations
Hematology Disease Topics & Pathways:
Clinical Trials, Bleeding and Clotting, Biological therapies, Antibody Therapy, Adults, Non-Biological therapies, Workforce, Health Outcomes Research, Chemotherapy, Elderly, Diversity, Equity, and Inclusion (DEI) , drug development, Diseases, thrombocytopenias, Therapies, Young Adults, Study Population, Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.)
Session: Managing Thrombocytopenia in Challenging Situations
Hematology Disease Topics & Pathways:
Clinical Trials, Bleeding and Clotting, Biological therapies, Antibody Therapy, Adults, Non-Biological therapies, Workforce, Health Outcomes Research, Chemotherapy, Elderly, Diversity, Equity, and Inclusion (DEI) , drug development, Diseases, thrombocytopenias, Therapies, Young Adults, Study Population, Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.)
Saturday, December 10, 2022, 4:00 PM-5:15 PM
Disclosures: Al-Samkari: Moderna: Consultancy; Forma: Consultancy; Amgen: Research Funding; Dova: Consultancy, Research Funding; argenx: Consultancy; Rigel: Consultancy; Novartis: Consultancy; Sobi: Consultancy, Research Funding; Agios: Consultancy, Research Funding.
OffLabel Disclosure: Romiplostim, eltrombopag, avatrombopag, hetrombopag for chemotherapy-induced thrombocytopenia
Previous Presentation
|
Next Presentation >>